The goals of this study were to determine the efficiency of PDC*line cells to activate and expand circulating tumor-antigen-specific CD8+ T cells (ASTC) from NSCLC patients and to know if the PDC*line-based vaccine can synergize with ICIs to boost the antitumor response. This evidence concerns the gene CD8A and non-small cell lung carcinoma.